Studies mostly in TLS patients confirmed that rasburicase application is safe, well tolerated and rapidly effective (onset is present already after 4 h) . The dramatic fall in serum UA levels is accompanied by rising diuresis. This prevents the need for dialysis among TLS patients, which is favorable and markedly reduces the costs of treatment. Hummel et al. 
gave low rasburicase doses in oncological patients, starting from 0.049 mg/kg/24 h and after that adjusting the dose to UA level with excellent effect. Rasburicase has been proven to dissolve tubular uric acid crystals. Segura et al.  postulated that rasburicase can also act in urinary tract, fragmentizing renal calculi, promoting relief of obstructive uropathy. They applied successfully rasburicase in 2 adults with acute obstructive nephropathy from renal calculi. De Angelis et al.  showed that after 7 days of the rasburicase Nutlin 3a more pronounced antihyperuricemic effect was obtained in men than in women with renal failure. In our boy with AKI we considered the use of rasburicase because of excessively elevated UA serum levels not resolving
after conservative management and to control volume of infused fluids and manage effective diuresis (Fig. 1c). Boy had cardiological complications – organic heart abnormality with pulmonary hypertension – and in his past history suffered cerebral stroke Daporinad solubility dmso and artificial mitral valve thrombosis. The instillation of hemodialysis carried higher risk, and as he had peritoneal dialysis and peritoneal drainage after cardiac surgery before, so we could expect the possibility of peritoneal adhesions. The treatment with one low-dose rasburicase (0.1 mg/kg body weight) was very efficient and prevented dialysis. Significant decline of UA serum levels (Fig. 1a) and normalization of renal indices (Fig. 1b) have been observed accompanied by metabolic alkalosis (Fig. 1d), hypokalemia (Fig. 1e), and hypocalcemia (Fig. 1f). Metabolic alterations after the use of rasburicase Bay 11-7085 required potassium and calcium supplementation
(risk of epileptic event). In line with our observations other authors shown that alkalinization could be withheld using rasburicase . Other effects of rasburicase include calcium phosphate tissue deposition caused by excessive phosphate reabsorption. Góth  described increased production and high concentration of hydrogen peroxide during rasburicase treatment. This could cause hemolysis and methemoglobin formation, in case of glucose-6-phosphate-dehydrogenase and catalase deficiencies. Roncal et al.  described in rats, that treatment with rasburicase reversed the inflammatory changes and lessened tubular injury with an improvement in renal function. During the prolonged treatment antibodies against rasburicase have been detected in serum of patients. These antibodies declined the treatment efficiency. It is hypothesized that UA might be directly involved in the apoptotic process. Hobbs et al.